阿尔茨海默病的影像与液体生物标志物:互补而非竞争
随着针对淀粉样蛋白的病因治疗问世,生物标志物辅助诊断阿尔茨海默病(AD)的作用进一步增强。本文讨论各类AD影像与液体生物标志物的优缺点,归类其互补而非冗余的价值,并提出用于可靠筛选淀粉样蛋白靶向治疗患者的整合生物标志物算法。
要点
- 淀粉样蛋白PET成像是公认的金标准,脑脊液诊断目前被建议用于治疗纳入和患者选择。
- 新型血液生物标志物正被引入,未来可能兼具诊断潜力和简便广泛的可得性。
- AD生物标志物分类指南仍在变动,各类生物标志物的角色尚未明确界定。
核心结论
- 本文尝试讨论各类AD影像与液体生物标志物的优缺点,并归类其互补、非冗余的价值以回答不同诊断问题。
- 作者提出一种整合生物标志物算法,用于可靠筛选适合淀粉样蛋白靶向治疗的AD患者。
研究设计与样本
- 本文为综述性文章,讨论AD影像与液体生物标志物的优缺点并提出整合生物标志物算法。
主要发现
- 淀粉样蛋白PET成像是公认的金标准。
- 脑脊液诊断目前被建议用于治疗纳入和患者选择。
- 新型血液生物标志物正被引入,具有诊断潜力并可能在未来简便广泛可及。
- AD生物标志物分类指南仍在变动,有时将生物标志物类别聚类而忽视其个体特征,导致分歧或有争议的讨论。
- 各类AD生物标志物的各自角色尚未明确界定。
关键数值与推荐
- 淀粉样蛋白PET成像是公认的金标准。
- 脑脊液诊断目前被建议用于治疗纳入和患者选择。
临床怎么用
- 作者提出一种整合生物标志物算法,用于可靠筛选适合淀粉样蛋白靶向治疗的AD患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the introduction of the new causal amyloid targeting therapies, the role of biomarker-assisted diagnosis of Alzheimer disease (AD) has received a further boost. In addition to the well-established gold standard, amyloid PET imaging, cerebrospinal fluid diagnostics are currently being suggested for therapy inclusion and patient selection. In addition, new types of blood-based biomarkers are being introduced, holding diagnostic potential together with potentially easy and broad accessibility in the future. In addition to the introduction of new biomarkers and new therapeutic approaches, the guidelines for biomarker-based classification of AD are also in flux, sometimes clustering biomarker classes and neglecting their individual characteristics, leading to divergent or controversial discussions. It is difficult to keep pace with these rapid developments, and the respective roles of the various AD biomarkers have not yet been clearly defined. Thus, in this paper, we attempt to discuss the strengths and weaknesses of the various imaging and fluid biomarkers of AD and classify what we consider to be their complementary, nonredundant value for various diagnostic questions. We propose an integrated biomarker algorithm for the purpose of reliable AD patient selection for amyloid targeting therapies.
引用
- Drzezga A, Barthel H. Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition. J Nucl Med. 2025. PMID: 40480828. doi:10.2967/jnumed.125.270152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。